VA-lip HSP47 resolves established skin fibrosis in chronic GVHD. Skin sickness in allogeneic recipients as compared with allogeneic recipients treated with VA-lip HSP47 (A). This reduced sickness is related due to reduced amount of collagen deposit in the skin of treated mice (B). This direct effect of VA-lip HSP47 on collagen deposit is illustrated by the 2 skin biopsies (C) of nontreated and VA-lip HSP47-treated recipients. Allo, allogeneic; Syn, syngeneic; VA-lip HSP47, vitamin A–coupled liposomes carrying HSP47 siRNA. The figure has been adapted from Figure 4 in the article by Yamakawa et al that begins on page 1476.